• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

医疗保健综合研究数据库(HIRD)作为药物流行病学研究的真实世界数据源。

The Healthcare Integrated Research Database (HIRD) as a Real-World Data Source for Pharmacoepidemiologic Research.

作者信息

Barron John J, Willey Vincent J, Doherty Brett T, Tunceli Ozgur, Waltz Craig R, Grabner Michael, Beachler Daniel C, Lanes Stephan, Cziraky Mark J

机构信息

Carelon Research, Wilmington, Delaware, USA.

出版信息

Pharmacoepidemiol Drug Saf. 2025 Feb;34(2):e70110. doi: 10.1002/pds.70110.

DOI:10.1002/pds.70110
PMID:39909722
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11798679/
Abstract

BACKGROUND AND METHODS

The Healthcare Integrated Research Database (HIRD) is a large, comprehensive real-world data (RWD) source for health-related research. Demographic and healthcare-related characteristics of individuals are sourced from routinely updated RWD. The HIRD includes health insurance claims and other health-related information for individuals enrolled in health insurance plans offered or managed by Elevance Health and has been utilized for research for almost two decades. Individuals in the HIRD reside throughout the United States. Data in the HIRD have been available since January 2006, and are updated monthly.

RESULTS

As of July 2024, the researchable population of the HIRD included over 91 million individuals with medical benefits, and over 24 million individuals were actively enrolled. The median age of individuals in the HIRD is 36 years (interquartile range [IQR]: 22, 54), and 50% of individuals in the HIRD are female. The median duration of continuous enrollment in the HIRD is 2.0 years (IQR: 0.8, 4.7). For those actively enrolled, the median duration of continuous enrollment is 3.8 years (IQR: 1.7, 8.3). Other important characteristics of the HIRD include the ability to trace data back to their source, support both deterministic and probabilistic linkage with external data sources, and link family members within health plans.

CONCLUSIONS

The HIRD has been a trusted resource to generate real-world evidence for a variety of health-related research, including regulatory-required safety studies, comparative effectiveness studies, and health economics and outcomes research.

摘要

背景与方法

医疗保健综合研究数据库(HIRD)是一个用于健康相关研究的大型、综合性真实世界数据(RWD)来源。个人的人口统计学和医疗保健相关特征源自定期更新的真实世界数据。HIRD包括参与由Elevance Health提供或管理的健康保险计划的个人的健康保险理赔及其他健康相关信息,并且已被用于研究近二十年。HIRD中的个人居住在美国各地。HIRD中的数据自2006年1月起可用,并每月更新。

结果

截至2024年7月,HIRD的可研究人群包括超过9100万享有医疗福利的个人,以及超过2400万活跃参保人员。HIRD中个人的年龄中位数为36岁(四分位间距[IQR]:22,54),且HIRD中50%的个人为女性。在HIRD中连续参保的时间中位数为2.0年(IQR:0.8,4.7)。对于那些活跃参保人员,连续参保的时间中位数为3.8年(IQR:1.7,8.3)。HIRD的其他重要特征包括能够将数据追溯到其来源、支持与外部数据源的确定性和概率性关联,以及在健康计划内关联家庭成员。

结论

HIRD一直是一个值得信赖的资源,可为各种健康相关研究生成真实世界证据,包括监管要求的安全性研究、比较有效性研究以及健康经济学和结果研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3c9/11798679/ed3cb5474e8d/PDS-34-e70110-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3c9/11798679/20032a5e2d16/PDS-34-e70110-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3c9/11798679/ed3cb5474e8d/PDS-34-e70110-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3c9/11798679/20032a5e2d16/PDS-34-e70110-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3c9/11798679/ed3cb5474e8d/PDS-34-e70110-g002.jpg

相似文献

1
The Healthcare Integrated Research Database (HIRD) as a Real-World Data Source for Pharmacoepidemiologic Research.医疗保健综合研究数据库(HIRD)作为药物流行病学研究的真实世界数据源。
Pharmacoepidemiol Drug Saf. 2025 Feb;34(2):e70110. doi: 10.1002/pds.70110.
2
Integration of administrative claims and clinical data to advance real-world evidence generation in oncology.整合行政索赔数据与临床数据以推动肿瘤学领域真实世界证据的生成。
Curr Med Res Opin. 2025 Apr;41(4):671-681. doi: 10.1080/03007995.2025.2482665. Epub 2025 Apr 9.
3
Overview of global real-world data sources for pediatric pharmacoepidemiologic research.儿科药物流行病学研究全球真实世界数据源概述。
Pharmacoepidemiol Drug Saf. 2024 Jan;33(1):e5695. doi: 10.1002/pds.5695. Epub 2023 Sep 10.
4
Concomitant asthma medication use in patients receiving omalizumab: results from three large insurance claims databases.接受奥马珠单抗治疗的患者同时使用哮喘药物的情况:来自三个大型保险理赔数据库的结果
J Asthma. 2011 Nov;48(9):923-30. doi: 10.3109/02770903.2011.618568. Epub 2011 Oct 7.
5
Pediatric Medical Subspecialist Use in Outpatient Settings.儿科医学亚专科医师在门诊环境中的应用。
JAMA Netw Open. 2024 Jan 2;7(1):e2350379. doi: 10.1001/jamanetworkopen.2023.50379.
6
Monitoring Pregnancies Exposed to Galcanezumab for Migraine in a United States Administrative Claims Database.在美国行政索赔数据库中监测暴露于加兰他敏的偏头痛妊娠情况。
Pharmacoepidemiol Drug Saf. 2024 Oct;33(10):e70015. doi: 10.1002/pds.70015.
7
Development of predictive models to identify advanced-stage cancer patients in a US healthcare claims database.开发预测模型,以在美国医疗保健索赔数据库中识别晚期癌症患者。
Cancer Epidemiol. 2019 Aug;61:30-37. doi: 10.1016/j.canep.2019.05.006. Epub 2019 May 22.
8
Real-world treatment patterns, resource utilization and costs in biliary tract cancers in the USA.美国胆道癌的真实世界治疗模式、资源利用和成本。
Future Oncol. 2024;20(34):2625-2636. doi: 10.1080/14796694.2024.2379237. Epub 2024 Aug 19.
9
Contemporary Practice and Considerations for Real-World Data Source Identification and Feasibility Assessment.当代真实世界数据源识别和可行性评估的实践与考量。
Pharmacoepidemiol Drug Saf. 2024 Sep;33(9):e5862. doi: 10.1002/pds.5862.
10
Healthcare resource utilization, treatment patterns, and cost of care among patients with thermal burns and inpatient autografting in two large privately insured populations in the United States.美国两个大型私人保险人群中热烧伤患者及住院自体移植患者的医疗资源利用、治疗模式及护理成本
Burns. 2020 Jun;46(4):825-835. doi: 10.1016/j.burns.2019.10.019. Epub 2019 Nov 22.

引用本文的文献

1
The impact of comorbidities on the prognosis of patients with septic arthritis.合并症对脓毒性关节炎患者预后的影响。
Front Med (Lausanne). 2025 Jun 18;12:1567229. doi: 10.3389/fmed.2025.1567229. eCollection 2025.
2
Burden of illness among patients with relapsed or refractory multiple myeloma, and eligible for B-cell maturation antigen-targeted therapies.复发或难治性多发性骨髓瘤患者且符合B细胞成熟抗原靶向治疗条件者的疾病负担
Future Oncol. 2025 Jul;21(17):2155-2165. doi: 10.1080/14796694.2025.2514399. Epub 2025 Jun 5.

本文引用的文献

1
Utilization and patient characteristics for the trastuzumab reference and biosimilars, and other human epidermal growth factor receptor 2 inhibitors in the United States.曲妥珠单抗原研药和生物类似药以及其他在美国使用的人表皮生长因子受体 2 抑制剂的利用情况和患者特征。
J Manag Care Spec Pharm. 2024 Oct;30(10):1160-1166. doi: 10.18553/jmcp.2024.30.10.1160.
2
Lessons on the use of real-world data in medical device research: findings from the National Evaluation System for Health Technology Test-Cases.医疗器械研究中真实世界数据应用的经验教训:国家卫生技术评估实例研究评价系统的研究结果。
J Comp Eff Res. 2024 Sep;13(9):e240078. doi: 10.57264/cer-2024-0078. Epub 2024 Aug 16.
3
Trends in the Completeness and Validity of Sources of Death Data Against the National Death Index From 2010 to 2018.
2010 年至 2018 年期间,死亡数据来源的完整性和有效性趋势与国家死亡索引相比。
Pharmacoepidemiol Drug Saf. 2024 Aug;33(8):e5870. doi: 10.1002/pds.5870.
4
Comparative safety of conjugated estrogens/bazedoxifene versus estrogen/progestin combination hormone therapy among women in the United States: a multidatabase cohort study.在美国女性中,结合雌激素/巴多昔芬与雌孕激素联合激素治疗的比较安全性:一项多数据库队列研究。
Menopause. 2023 Aug 1;30(8):824-830. doi: 10.1097/GME.0000000000002217. Epub 2023 Jul 11.
5
Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial.在每周一次皮下注射司美格鲁肽的随机、实用(SEPRA)试验中,2 型糖尿病成人患者的研究设计和基线概况。
BMJ Open Diabetes Res Care. 2023 May;11(3). doi: 10.1136/bmjdrc-2022-003206.
6
Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer.静脉血栓栓塞症发生率及相关风险因素与晚期非小细胞肺癌患者免疫检查点抑制剂治疗。
J Immunother Cancer. 2023 Jan;11(1). doi: 10.1136/jitc-2022-006072.
7
Using the IMEDS distributed database for epidemiological studies in type 2 diabetes mellitus.利用 IMEDS 分布式数据库进行 2 型糖尿病的流行病学研究。
BMJ Open Diabetes Res Care. 2022 Dec;10(6). doi: 10.1136/bmjdrc-2022-002916.
8
Real-world data: a brief review of the methods, applications, challenges and opportunities.真实世界数据:方法、应用、挑战和机遇的简要回顾。
BMC Med Res Methodol. 2022 Nov 5;22(1):287. doi: 10.1186/s12874-022-01768-6.
9
Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases.美国 COVID-19 mRNA 疫苗接种后的心肌炎和心包炎风险:索赔数据库中的队列研究。
Lancet. 2022 Jun 11;399(10342):2191-2199. doi: 10.1016/S0140-6736(22)00791-7.
10
Real-world data: Assessing electronic health records and medical claims data to support regulatory decision-making for drug and biological products.真实世界数据:评估电子健康记录和医疗理赔数据以支持药品和生物制品的监管决策。
Pharmacoepidemiol Drug Saf. 2022 Jul;31(7):717-720. doi: 10.1002/pds.5444. Epub 2022 May 3.